Denosumab in Treating Patients with Bone Loss due to Donor Stem Cell Transplant

Status: Approved


This phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, leading to a decrease in satisfaction and quality of life. A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down.

Eligibility Criteria

Inclusion Criteria

  • The patient has undergone an allogeneic hematopoietic stem cell transplant
  • The patient has completed a base line dual x-ray absorptiometry (DXA) scan =< 3 months prior to transplantation
  • The patient has completed a post-transplant DXA scan at day 100 (+/- 30 days) post transplantation
  • The patients’ post-transplantation DXA scan denotes one or more of the following: * >= 5% decrease in bone mineral density (g/cm^2) in either the dual femur or lumbar spine (average of L1-L4), or both, between the pre-hematopoietic stem cell transplant (HSCT) and ~ day + 100 post-HSCT DXA scans * Osteopenia in either the dual femur or lumbar spine (L1-L4) at either the pre-HSCT or day + 100 post-HSCT timepoint * Osteoporosis in either the dual femur or lumbar spine (L1-L4) at either the pre-HSCT or day + 100 post-HSCT timepoint
  • The patient has completed and passed a dental clearance exam for administration of denosumab
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria

  • The patient has a history of a hypersensitivity reaction to denosumab
  • The patient has a history of osteonecrosis of the jaw
  • The patient has predisposing risk factors for hypocalcemia including the following: * Hypoparathyroidism * Creatinine clearance (CrCl) < 30 mL/min * Dialysis * Malabsorption syndrome
  • The patient has history of any bone fracture =< 30 days prior to denosumab therapy
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator’s opinion deems the participant an unsuitable candidate to receive study drug including relapsed malignancy

Locations & Contacts

New York

Roswell Park Cancer Institute
Status: Approved
Contact: Philip L. McCarthy
Phone: 716-845-8412

Trial Objectives and Outline


I. To evaluate the efficacy and safety of denosumab therapy for the treatment of bone loss in patients who have received an allogeneic hematopoietic stem cell transplant.


Patients receive 2 doses of denosumab subcutaneously (SC) between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.

After completion of study treatment patients are followed up at 6 months.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Supportive care

Lead Organization

Lead Organization
Roswell Park Cancer Institute

Principal Investigator
Philip L. McCarthy

Trial IDs

Primary ID I 78618
Secondary IDs NCI-2019-01921 ID NCT03925532